@article{Raouf Ben Abdelali_Vahid Asnafi_Arnaud Petit_Jean-Baptiste Micol_Céline Callens_Patrick Villarese_Eric Delabesse_Oumedaly Reman_Stephane Lepretre_Jean-Yves Cahn_Gaelle Guillerm_Céline Berthon_Claude Gardin_Bernadette Corront_Thibaut Leguay_Marie-Christine Béné_Norbert Ifrah_Guy Leverger_Hervé Dombret_Elizabeth Macintyre_2013, place={Pavia, Italy}, title={The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest}, volume={98}, url={https://haematologica.org/article/view/6833}, DOI={10.3324/haematol.2013.086082}, abstractNote={CALM-AF10 (also known as PICALM-MLLT10) is the commonest fusion protein in T-cell acute lymphoblastic leukemia, but its prognostic impact remains unclear. Molecular screening at diagnosis identified <em>CALM-AF10</em> in 30/431 (7%) patients with T-cell acute lymphoblastic leukemia aged 16 years and over and in 15/234 (6%) of those aged up to 15 years. Adult <em>CALM-AF10</em>-positive patients were predominantly (72%) negative for surface (s)CD3/T-cell receptor, whereas children were predominantly (67%) positive for T-cell receptor. Among 22 adult <em>CALM-AF10</em>-positive patients treated according to the LALA94/GRAALL03-05 protocols, the poor prognosis for event-free survival (<em>P</em>=0.0017) and overall survival (<em>P</em>=0.0014) was restricted to the 15 T-cell receptor-negative cases. Among <em>CALM-AF10</em>-positive, T-cell receptor-negative patients, 82% had an early T-cell precursor phenotype, reported to be of poor prognosis in pediatric T-cell acute lymphoblastic leukemia. Early T-cell precursor acute lymphoblastic leukemia corresponded to 22% of adult LALA94/GRAALL03-05 T-cell acute lymphoblastic leukemias, but had no prognostic impact <em>per se. CALM-AF10</em> fusion within early T-cell precursor acute lymphoblastic leukemia (21%) did, however, identify a group with a poor prognosis with regards to event-free survival (<em>P</em>=0.04). <em>CALM-AF10</em> therefore identifies a poor prognostic group within sCD3/T-cell receptor negative adult T-cell acute lymphoblastic leukemias and is over-represented within early T-cell precursor acute lymphoblastic leukemias, in which it identifies patients in whom treatment is likely to fail. Its prognosis and overlap with early T-cell precursor acute lymphoblastic leukemia in pediatric T-cell acute lymphoblastic leukemia merits analysis. <em>The clinical trial GRAALL was registered at Clinical Trials.gov number <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT00327678&amp;atom=%2Fhaematol%2F98%2F11%2F1711.atom">NCT00327678</a>.</em&gt;}, number={11}, journal={Haematologica}, author={Raouf Ben Abdelali and Vahid Asnafi and Arnaud Petit and Jean-Baptiste Micol and Céline Callens and Patrick Villarese and Eric Delabesse and Oumedaly Reman and Stephane Lepretre and Jean-Yves Cahn and Gaelle Guillerm and Céline Berthon and Claude Gardin and Bernadette Corront and Thibaut Leguay and Marie-Christine Béné and Norbert Ifrah and Guy Leverger and Hervé Dombret and Elizabeth Macintyre}, year={2013}, month={Nov.}, pages={1711-1717} }